ADC Therapeutics

ADC Therapeutics develops proprietary antibody-drug conjugates for the treatment of solid and hematological cancers. Read more

183 Followers on Owler
183 Followers on Owler
183 Followers on Owler
183 Followers on Owler

ADC Therapeutics

ADC Therapeutics develops proprietary antibody-drug conjugates for the treatment of solid and hematological cancers. Read more

Chris Martin's photo - Co-Founder & CEO of ADC Therapeutics

Co-Founder & CEO

Chris Martin

CEO Approval Rating

89/100

Founded:

2011

Status:

PublicIndependent CompanyNYSEADCT

ADC THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Astellas Pharma, Inc. is perceived as one of ADC Therapeutics's biggest rivals. Astellas Pharma, Inc. is headquartered in Tokyo, Tōkyō Prefecture, and was founded in 2005. Astellas Pharma, Inc. operates in the Pharmaceuticals industry. Astellas Pharma, Inc. generates -4819.41% the revenue of ADC Therapeutics.

CytomX is one of ADC Therapeutics's top competitors. CytomX is a Public company that was founded in 2008 in South San Francisco, California. Like ADC Therapeutics, CytomX also competes in the Biotechnology field. Compared to ADC Therapeutics, CytomX has 62 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is ImmunoGen a competitor of ADC Therapeutics?

ADC Therapeutics Quarterly and Annual Revenue

Coming soon for ADC Therapeutics!

Annual Revenue

$ < 1M

ADC Therapeutics Acquisitions

No recent acquisitions found related to ADC Therapeutics

ADC Therapeutics Funding History

Since ADC Therapeutics was founded in 2011, it has participated in 7 rounds of funding. In total ADC Therapeutics has raised $758.7M. ADC Therapeutics' last funding round was on May 2020 for a total of $232.7M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
May 2020
$232.7M

Series E
Jul 2019
$25M
-
Series E
Jun 2019
$76M
-
Series E
Oct 2017
$200M
Private Equity Round
Oct 2016
$105M

Since ADC Therapeutics was founded in 2011, it has participated in 7 rounds of funding. In total ADC Therapeutics has raised $758.7M. ADC Therapeutics' last funding round was on May 2020 for a total of $232.7M

ADC Therapeutics Investments

No recent investments found related to ADC Therapeutics

ADC Therapeutics News

May 5, 2021Markets Insider

ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of... See more »
April 29, 2021ChinaBio Today

Adcentrx Raises $50 Million in Initial Funding for Novel ADC Therapies

Adcentrx Therapeutics. a Shanghai-San Diego startup, closed a $50 million Series A financing to devel... See more »
April 29, 2021Markets Insider

ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of... See more »
April 27, 2021startupticker

ADC Therapeutics obtains its first FDA approval for its Lymphoma cancer treatment

The U.S. Food and Drug Administration has approved ACD Therapeutics' lead drug candidate ZYNLONTA for... See more »
April 26, 2021MedCity News

FDA approves ADC Therapeutics antibody drug conjugate in B-cell lymphoma

With FDA approval of Zynlonta, ADC Therapeutics can offer patients who have diffuse large B-cell lymp... See more »
April 26, 2021BioPharma-Reporter

ADC Therapeutics gets the nod from the FDA for its CD19-targeted antibody drug conjugate

The US Food and Drug Administration (FDA) has approved ADC Therapeuticsâ ZYNLONTA as a third-line the... See more »

ADC Therapeutics Press Releases

October 9, 2020Business Wire

ADC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Common Shares

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncol... See more »
April 24, 2020centralcharts

ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering

EQS Group-News: ADC Therapeutics SA / Key word(s): IPO ADC Therapeutics Files Registration Statement ... See more »
March 5, 2018Webnewswire

Antibody Drug Conjugates at the Forefront of Treating Hematological Malignancies

"Increasing number of novel Antibody Drug Conjugates are being developed for the treatment of varied ... See more »
November 15, 2017Business Wire

ADC Therapeutics to Present New Clinical Data for ADCT-402 and ADCT-301 at the American Society of Hematology 2017 Annual Meeting

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics (ADCT), an oncology drug discovery and devel... See more »
September 4, 2017BriefingWire

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)-Pipeline Review, H2 2017

ReportsWeb.com published "Hodgkin Lymphoma Market" from its database. The report covers the market la... See more »
January 5, 2017PRFree

ADC Therapeutics SA - Product Pipeline Review - 2016

'ADC Therapeutics SA - Product Pipeline Review - 2016', provides an overview of the ADC Therapeutics ... See more »
November 8, 2016NewsMaker

Relapsed Acute Myeloid Leukemia - Pipeline Review, H2 2016

The report provides comprehensive information on the therapeutics under development for Relapsed Acut... See more »

ADC Therapeutics Videos

Social Media

ADC Therapeutics Headquarters

Route de la Corniche 3B

Epalinges, Vaud1066

41-21-653-02-00

Driving Directions »

Trending Companies

ADC Therapeutics Summary

ABOUT

Overview

ADC Therapeutics develops proprietary antibody-drug conjugates for the treatment of solid and hematological cancers. ADC Therapeutics was founded in 2011. ADC Therapeutics' headquarters is located in Epalinges, Vaud, CH 1066. It has raised 758.7M in 7...

CEO

ADC Therapeutics's Co-Founder & CEO, Chris Martin, currently has an approval rating of 89%. ADC Therapeutics's primary competitors are Astellas Pharma, Inc., CytomX & Seattle Genetics.

Website

adctherapeutics.com

Frequently Asked Questions about ADC Therapeutics

  1. When was ADC Therapeutics founded?

    ADC Therapeutics was founded in 2011
  2. Who is ADC Therapeutics's CEO?

    ADC Therapeutics's CEO is Chris Martin
  3. How much revenue does ADC Therapeutics generate?

    ADC Therapeutics generates $ < 1M in revenue
  4. How much funding does ADC Therapeutics have?

    ADC Therapeutics has historically raised $758.7M in funding
  1. Where is ADC Therapeutics's headquarters?

    ADC Therapeutics's headquarters is in Epalinges Vaud, CH
  2. How many employees does ADC Therapeutics have?

    ADC Therapeutics has 208 employees
  3. What sector does ADC Therapeutics operate in?

    ADC Therapeutics is in Biotechnology
  4. Who are ADC Therapeutics's competitors?

    ADC Therapeutics's top competitors are Astellas Pharma, Inc., CytomX, Seattle Genetics